MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Novartis Pharmaceuticals (Industry)
Overall Status
Available ID

Study Details

Study Description

Brief Summary

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Condition or Disease Intervention/Treatment Phase

Detailed Description

The requesting Treating Physician must submit a request for access to drug (often referred to as Compassionate Use) to Novartis which will review and approve by the medical team experienced with the drug and indication.

Study Design

Study Type:
Expanded Access
Official Title:
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV)

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria


    Ages Eligible for Study:
    12 Years to 99 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:

    Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

    1. Male or female aged 12 or over

    2. Confirmed diagnosis of PV based on World Health Organization (WHO) criteria

    3. Patients must have a treatment history for PV that meets the definition of resistance or intolerance to hydroxyurea (HU) or other cytoreductive therapy

    4. Patients with a peripheral blood blast count of 0% at screening

    5. Patients must have recovered or stabilized sufficiently from adverse drug reactions associated with prior treatments before beginning treatment with ruxolitinib

    6. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 Written patient informed consent must be obtained prior to start of treatment.

    Exclusion Criteria:
    Patients eligible for this Treatment Plan must not meet any of the following criteria:
    1. History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib.

    2. Presence of an active uncontrolled infection including significant bacterial, fungal, viral (including CMV, EBV, HHV-6, HBV, HCV, BK or HIV) or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. Patients with inactive chronic infection (without viral replication) can be enrolled.

    3. History of progressive multifocal leuko-encephalopathy (PML).

    4. Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 ╬╝mol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation.

    5. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are

    • women whose sexual orientation precludes intercourse with a male partner.

    • women whose partners have been sterilized by vasectomy or other means.

    • using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable throughout the period of treatment and 30 days after treatment discontinuation.

    Any female aged 8 years and above is to be treated as a woman of child-bearing potential.

    Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

    1. Pregnancy

    2. Not able to understand and to comply with treatment instructions and requirements

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • Novartis Pharmaceuticals


    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Novartis Pharmaceuticals Identifier:
    Other Study ID Numbers:
    • CINC424B2002I
    First Posted:
    Mar 8, 2022
    Last Update Posted:
    Mar 8, 2022
    Last Verified:
    Feb 1, 2022
    Keywords provided by Novartis Pharmaceuticals
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 8, 2022